DIP2C

Summary

DIP2C (DIP2 acetate–CoA ligase C (putative), HGNC:29150) is a protein-coding gene on chromosome 10p15.3, encoding Disco-interacting protein 2 homolog C (Q9Y2E4).

This gene encodes a member of the disco-interacting protein homolog 2 family. The protein shares strong similarity with a Drosophila protein which interacts with the transcription factor disco and is expressed in the nervous system.

Source: NCBI Gene 22982 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Definitive, GenCC) — +1 more curated relationship
• GWAS associations: 10
• Clinical variants (ClinVar): 1,100 total — 15 pathogenic, 8 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_014974

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29150
Approved symbol	DIP2C
Name	DIP2 acetate–CoA ligase C (putative)
Location	10p15.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000151240
Ensembl biotype	protein_coding
OMIM	611380
Entrez	22982

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000280886, ENST00000421992, ENST00000434695, ENST00000634311, ENST00000891378, ENST00000891379, ENST00000931129

RefSeq mRNA: 1 — MANE Select: NM_014974 NM_014974

CCDS: CCDS7054

Canonical transcript exons

ENST00000280886 — 37 exons

Exon	Start	End
ENSE00000998466	387745	387809
ENSE00000998467	390264	390373
ENSE00000998471	390740	390863
ENSE00000998472	384027	384146
ENSE00000998474	366275	366411
ENSE00000998475	389991	390093
ENSE00000998476	382647	382761
ENSE00000998489	348641	348762
ENSE00001094383	327006	327176
ENSE00001094397	349331	349454
ENSE00001094398	329433	329601
ENSE00001094404	356426	356506
ENSE00001263841	281200	281323
ENSE00001263855	286273	286347
ENSE00001263861	288364	288421
ENSE00001609877	413913	414110
ENSE00001633943	310031	310092
ENSE00001645967	341199	341329
ENSE00001657039	419065	419199
ENSE00001657828	344809	344918
ENSE00001669560	422824	423033
ENSE00001675153	408926	409017
ENSE00001710343	689494	689668
ENSE00001718350	344999	345110
ENSE00001735549	399109	399219
ENSE00001771278	384546	384639
ENSE00001773986	283272	283446
ENSE00001775446	415769	415888
ENSE00003483266	369494	369633
ENSE00003500812	486459	486530
ENSE00003715003	362490	362691
ENSE00003716620	364374	364582
ENSE00003721721	440871	440996
ENSE00003724665	363197	363311
ENSE00003734646	472439	472549
ENSE00003746467	357828	357937
ENSE00003785622	274201	277577

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 95.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.6813 / max 150.0786, expressed in 1534 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
107856	10.0493	1445
107858	0.9528	532
107836	0.2094	108
205703	0.1732	74
107857	0.1613	65
107837	0.0771	24
107840	0.0356	19
107838	0.0148	5
107839	0.0078	2

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	95.29	gold quality
middle frontal gyrus	UBERON:0002702	95.03	gold quality
paraflocculus	UBERON:0005351	94.76	gold quality
tibia	UBERON:0000979	94.73	gold quality
middle temporal gyrus	UBERON:0002771	94.46	gold quality
saphenous vein	UBERON:0007318	94.41	gold quality
quadriceps femoris	UBERON:0001377	94.25	gold quality
vastus lateralis	UBERON:0001379	94.24	gold quality
endothelial cell	CL:0000115	93.91	gold quality
CA1 field of hippocampus	UBERON:0003881	93.79	gold quality
gluteal muscle	UBERON:0002000	93.57	gold quality
deltoid	UBERON:0001476	93.46	gold quality
nephron tubule	UBERON:0001231	93.44	gold quality
frontal pole	UBERON:0002795	93.26	gold quality
lateral globus pallidus	UBERON:0002476	93.10	gold quality
cerebellar vermis	UBERON:0004720	93.10	gold quality
triceps brachii	UBERON:0001509	93.07	gold quality
biceps brachii	UBERON:0001507	93.04	gold quality
blood vessel layer	UBERON:0004797	92.87	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.76	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	92.75	gold quality
tibialis anterior	UBERON:0001385	92.32	gold quality
skeletal muscle tissue	UBERON:0001134	92.31	gold quality
Brodmann (1909) area 23	UBERON:0013554	92.10	gold quality
Brodmann (1909) area 10	UBERON:0013541	92.06	gold quality
Brodmann (1909) area 46	UBERON:0006483	91.95	gold quality
heart right ventricle	UBERON:0002080	91.74	gold quality
cranial nerve II	UBERON:0000941	91.72	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.36	gold quality
left ventricle myocardium	UBERON:0006566	91.04	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.64
E-ENAD-17	no	111.88

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

211 targeting DIP2C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3065-5P	99.97	71.56	3281

Literature-anchored findings (GeneRIF, showing 6)

• This publication discusses the expression pattern and potential function of similar genes in Drosophila and mouse. (PMID:12137943)
• DIP2C gene SNP rs877282 reached genome-wide significant association with plasma uric acid levels (P = 4.56 x 10(-8)). (PMID:23703922)
• Loss of DIP2C triggers substantial DNA methylation and gene expression changes, cellular senescence and epithelial-mesenchymal transition in cancer cells. (PMID:28716088)
• The data revealed DIP2C expression level decreased in breast cancer, especially in basal-like and HER-2 subtypes, and could be a valuable target for diagnosis on specific subtype of breast cancer (PMID:28964575)
• DIP2C polymorphisms are implicated in susceptibility and clinical phenotypes of autism spectrum disorder. (PMID:35987071)
• De novo variants predicting haploinsufficiency for DIP2C are associated with expressive speech delay. (PMID:38421105)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	dip2ca	ENSDARG00000062154
mus_musculus	Dip2c	ENSMUSG00000048264
rattus_norvegicus	Dip2c	ENSRNOG00000015288
drosophila_melanogaster	DIP2	FBGN0024806
caenorhabditis_elegans	dip-2	WBGENE00017885

Paralogs (2): DIP2B (ENSG00000066084), DIP2A (ENSG00000160305)

Protein

Protein identifiers

Disco-interacting protein 2 homolog C — Q9Y2E4 (reviewed: Q9Y2E4)

All UniProt accessions (4): Q9Y2E4, A0A0U1RQW6, H0Y5A8, H0Y7Q3

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the DIP2 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y2E4-1	1	yes
Q9Y2E4-2	2

RefSeq proteins (1): NP_055789* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000873	AMP-dep_synth/lig_dom	Domain
IPR010506	DMAP1-bd	Domain
IPR025110	AMP-bd_C	Domain
IPR037337	Dip2-like_dom	Domain
IPR042099	ANL_N_sf	Homologous_superfamily
IPR045851	AMP-b_sf	Homologous_superfamily

Pfam: PF00501, PF06464, PF23024

UniProt features (15 total): compositionally biased region 4, splice variant 3, sequence variant 3, region of interest 2, chain 1, domain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2E4-F1	79.64	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 264

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 179 (showing top): GCACCTT_MIR18A_MIR18B, AAGCCAT_MIR135A_MIR135B, MORF_FANCG, AACTTT_UNKNOWN, TAATGTG_MIR323, MORF_IKBKG, CTTTGTA_MIR524, MODULE_207, chr10p15, YAGI_AML_WITH_11Q23_REARRANGED, AACATTC_MIR4093P, ATGTACA_MIR493, ATCTTGC_MIR31, MODULE_534, GTATTAT_MIR3693P

GO Biological Process (1): biological_process (GO:0008150)

GO Molecular Function (1): molecular_function (GO:0003674)

GO Cellular Component (1): cellular_component (GO:0005575)

Protein interactions and networks

STRING

2896 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DIP2C	WDR37	Q9Y2I8	604
DIP2C	ZMYND11	Q15326	595
DIP2C	DMAP1	Q9NPF5	578
DIP2C	LARP4B	Q92615	546
DIP2C	DIP2C-AS1	Q8N8Z3	526
DIP2C	IDI2	Q9BXS1	464
DIP2C	GNG7	O60262	454
DIP2C	FAM47A	Q5JRC9	446
DIP2C	PFKP	Q01813	444
DIP2C	DCAF12	Q5T6F0	444
DIP2C	DLEU7	Q6UYE1	443
DIP2C	GASK1B	Q6UWH4	438
DIP2C	STK33	Q9BYT3	427
DIP2C	G2E3	Q7L622	425
DIP2C	ANKS1B	Q7Z6G8	417

IntAct

9 interactions, top by confidence:

A	B	Type	Score
PIP4K2A	AP3B1	psi-mi:“MI:0914”(association)	0.530
PCBD1	DIP2C	psi-mi:“MI:0915”(physical association)	0.370
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
PIP4K2C	AP3B1	psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
KCNE3	TMEM131L	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): DIP2C (Affinity Capture-MS), DIP2C (Affinity Capture-RNA), DIP2C (Affinity Capture-RNA), DIP2C (Affinity Capture-MS), DIP2C (Affinity Capture-MS), DIP2C (Affinity Capture-MS), DIP2C (Affinity Capture-MS), DIP2C (Affinity Capture-RNA), DIP2C (Affinity Capture-MS), DIP2C (Affinity Capture-RNA), DIP2C (Two-hybrid)

ESM2 similar proteins: A0P9L2, A4D1P6, A9JTG5, B2RYI0, B8JKF4, D4A7V9, F1LW30, O08721, O08722, O14976, P0CI65, P57075, P97874, Q08AV8, Q14689, Q17QN2, Q17RB8, Q1L5Z9, Q1LXR6, Q1LXZ7, Q2HJE1, Q2I6J0, Q32PH0, Q3U0M1, Q3UH60, Q501X6, Q568P9, Q5R6T6, Q5RAR6, Q5RB40, Q5ZLL7, Q6DE55, Q6TEN6, Q6UXZ4, Q6ZN44, Q6ZPG2, Q7T2Z5, Q7TMQ7, Q8BWT5, Q8IZJ1

Diamond homologs: Q14689, Q3UH60, Q6NVJ5, Q8BWT5, Q9P265, Q9W0S9, Q9Y2E4, Q69ZN6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1100 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	15
Likely pathogenic	8
Uncertain significance	437
Likely benign	517
Benign	74

Top pathogenic / likely-pathogenic (23)

Variant ID	HGVS	Classification
2120391	NM_014974.3(DIP2C):c.3323_3341dup (p.Asp1115fs)	Pathogenic
222072	NC_000010.10:g.(?116476)(450983_?)del	Pathogenic
2862727	NM_014974.3(DIP2C):c.2397_2398dup (p.Ser800fs)	Pathogenic
3652490	NM_014974.3(DIP2C):c.2875C>T (p.Gln959Ter)	Pathogenic
3677218	NM_014974.3(DIP2C):c.1834_1835del (p.Ser612fs)	Pathogenic
4011773	NM_014974.3(DIP2C):c.2590C>T (p.Gln864Ter)	Pathogenic
4011774	NM_014974.3(DIP2C):c.2310C>A (p.Tyr770Ter)	Pathogenic
4071587	NM_014974.3(DIP2C):c.1146_1147dup (p.Arg383fs)	Pathogenic
4082560	NM_014974.3(DIP2C):c.2208_2209del (p.Ala737fs)	Pathogenic
4240675	NM_014974.3(DIP2C):c.238dup (p.Ser80fs)	Pathogenic
4240676	NM_014974.3(DIP2C):c.4153del (p.Tyr1385fs)	Pathogenic
4686180	NM_014974.3(DIP2C):c.247C>T (p.Arg83Ter)	Pathogenic
563772	GRCh37/hg19 10p15.3(chr10:116045-1573221)x1	Pathogenic
688593	GRCh37/hg19 10p15.3(chr10:100026-692028)x1	Pathogenic
815308	GRCh37/hg19 10p15.3(chr10:100026-820189)x1	Pathogenic
1465565	NM_014974.3(DIP2C):c.3110-2A>G	Likely pathogenic
148280	GRCh38/hg38 10p15.3(chr10:70478-312686)x1	Likely pathogenic
150117	GRCh38/hg38 10p15.3(chr10:70478-770688)x1	Likely pathogenic
150324	GRCh38/hg38 10p15.3(chr10:70478-1042794)x1	Likely pathogenic
3502059	NM_014974.3(DIP2C):c.4399del (p.His1467fs)	Likely pathogenic
3900347	NM_014974.3(DIP2C):c.3453+5G>C	Likely pathogenic
4279917	NM_014974.3(DIP2C):c.1756+1dup	Likely pathogenic
4280662	NM_014974.3(DIP2C):c.1167del (p.Asn390fs)	Likely pathogenic

SpliceAI

13307 predictions. Top by Δscore:

Variant	Effect	Δscore
10:277573:CAGCA:C	acceptor_gain	1.0000
10:277574:AGCA:A	acceptor_gain	1.0000
10:277575:GCA:G	acceptor_gain	1.0000
10:277575:GCACT:G	acceptor_loss	1.0000
10:277576:CA:C	acceptor_gain	1.0000
10:277576:CAC:C	acceptor_gain	1.0000
10:277577:AC:A	acceptor_loss	1.0000
10:277578:C:CC	acceptor_gain	1.0000
10:277578:CT:C	acceptor_loss	1.0000
10:288359:CTTA:C	donor_loss	1.0000
10:288361:TA:T	donor_loss	1.0000
10:288363:C:CA	donor_loss	1.0000
10:288363:CCTTT:C	donor_gain	1.0000
10:288420:CT:C	acceptor_gain	1.0000
10:327464:T:TA	donor_gain	1.0000
10:329427:GCTTA:G	donor_loss	1.0000
10:329428:CTTAC:C	donor_loss	1.0000
10:329429:TTACC:T	donor_loss	1.0000
10:329430:TACC:T	donor_loss	1.0000
10:329431:A:AC	donor_gain	1.0000
10:329431:A:AT	donor_loss	1.0000
10:329432:C:CC	donor_gain	1.0000
10:329432:C:CT	donor_loss	1.0000
10:329598:CACA:C	acceptor_gain	1.0000
10:329600:CA:C	acceptor_gain	1.0000
10:329602:C:CC	acceptor_gain	1.0000
10:341193:TCTTA:T	donor_loss	1.0000
10:341194:CTTA:C	donor_loss	1.0000
10:341195:TTA:T	donor_loss	1.0000
10:341196:TA:T	donor_loss	1.0000

AlphaMissense

10084 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:277370:A:C	F1542L	1.000
10:277370:A:T	F1542L	1.000
10:277371:A:G	F1542S	1.000
10:277372:A:G	F1542L	1.000
10:277383:A:G	L1538P	1.000
10:277393:G:T	R1535S	1.000
10:277394:C:A	Q1534H	1.000
10:277394:C:G	Q1534H	1.000
10:283310:C:T	G1419E	1.000
10:283311:C:A	G1419W	1.000
10:283311:C:G	G1419R	1.000
10:283311:C:T	G1419R	1.000
10:329537:A:G	W1217R	1.000
10:329537:A:T	W1217R	1.000
10:348702:A:T	V1057D	1.000
10:357901:A:T	V944D	1.000
10:357904:A:G	L943P	1.000
10:357910:C:T	G941E	1.000
10:357911:C:A	G941W	1.000
10:357911:C:G	G941R	1.000
10:357911:C:T	G941R	1.000
10:363217:A:G	W858R	1.000
10:363217:A:T	W858R	1.000
10:364410:A:G	L814P	1.000
10:364419:G:T	A811D	1.000
10:364515:C:T	G779E	1.000
10:382736:A:C	F634L	1.000
10:382736:A:T	F634L	1.000
10:382737:A:G	F634S	1.000
10:382738:A:G	F634L	1.000

dbSNP variants (sampled 300 via entrez): RS1000010531 (10:616108 G>T), RS1000011425 (10:428198 T>C), RS1000012623 (10:359901 G>A), RS1000021505 (10:373559 T>TA), RS1000039427 (10:625213 A>G), RS1000047523 (10:518793 C>G), RS1000048212 (10:400356 G>A,C), RS1000051781 (10:461151 A>G), RS1000052191 (10:626190 C>G,T), RS1000053299 (10:599083 C>G,T), RS1000054258 (10:370859 A>G,T), RS1000070042 (10:665488 C>T), RS1000079402 (10:619551 C>A,T), RS1000081395 (10:503368 A>C,T), RS1000084433 (10:511771 C>T)

Disease associations

OMIM: gene MIM:611380 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Definitive	Autosomal dominant
neurodevelopmental disorder	Strong	Autosomal dominant

Mondo (3): neurodevelopmental disorder (MONDO:0700092), obesity disorder (MONDO:0011122), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (2): Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001513	Obesity

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001282_5	Psychosis in Alzheimer’s disease	8.000000e-06
GCST001538_27	Immune reponse to smallpox (secreted IFN-alpha)	1.000000e-07
GCST001801_4	Uric acid levels	5.000000e-08
GCST007576_240	Chronotype	2.000000e-10
GCST009209_9	Frontal pole volume	9.000000e-07
GCST009218_25	Lateral ventricle temporal horn volume	6.000000e-06
GCST010151_18	Carotid intima media thickness x smoking interaction	8.000000e-07
GCST010396_315	Gut microbiota (bacterial taxa, hurdle binary method)	6.000000e-06
GCST010725_32	Malaria	2.000000e-07
GCST010725_99	Malaria	8.000000e-08

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0005940	psychotic symptoms
EFO:0004645	response to vaccine
EFO:0004873	cytokine measurement
EFO:0004761	uric acid measurement
EFO:0008328	chronotype measurement
EFO:0006527	smoking status measurement
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression	4
sodium arsenite	affects methylation, decreases expression, increases expression	3
Valproic Acid	decreases expression, increases expression, increases methylation	3
bisphenol A	affects cotreatment, decreases methylation, affects methylation	2
Smoke	decreases expression, increases expression	2
Aflatoxin B1	affects expression, increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, affects methylation	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
titanium dioxide	increases expression	1
trichostatin A	decreases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
aflatoxin B2	affects methylation	1
beta-methylcholine	affects expression	1
CGP 52608	increases reaction, affects binding	1
bisphenol S	increases methylation	1
jinfukang	affects cotreatment, decreases expression	1
Decitabine	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, affects methylation	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Cisplatin	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

204 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism